Yuan Cheng1, Yahong Luo2, Yue Hu1, Zhaohe Zhang2, Xingling Wang2, Qing Yu2, Guanyu Liu2, Enuo Cui3, Tao Yu2, Xiran Jiang4. 1. Department of Biomedical Engineering, School of Fundamental Sciences, China Medical University, Shenyang, 110122, People's Republic of China. 2. Department of Radiology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, 110042, People's Republic of China. 3. School of Computer Science and Engineering, Shenyang University, Shenyang, 110044, People's Republic of China. 4. Department of Biomedical Engineering, School of Fundamental Sciences, China Medical University, Shenyang, 110122, People's Republic of China. xrjiang@cmu.edu.cn.
Abstract
PURPOSE: To investigate the value of multiparametric MRI-based radiomics on predicting response to nCRT in patients with rectal cancer. METHODS: This study enrolled 193 patients with pathologically confirmed LARC who received nCRT treatment between Apr. 2014 and Jun. 2018. All patients underwent baseline T1-weighted (T1W), T2-weighted (T2W) and T2-weighted fat-suppression (T2FS) MRI scans before neoadjuvant chemoradiotherapy. Radiomics features were extracted and selected from the MRI data to establish the radiomics signature. Important clinical predictors were identified by Mann-Whitney U test and Chi-square test. The nomogram integrating the radiomics signature and important clinical predictors was constructed using multivariate logistic regression. Prediction capabilities of each model were assessed with receiver operating characteristic (ROC) curve analysis. Performance of the nomogram was evaluated by its calibration and potential clinical usefulness. RESULTS: For the prediction of good response (GR) and pathologic complete response (pCR), the developed radiomics signature comprising 10 and 7 features, respectively, were significantly associated with the therapeutic response to nCRT. The nomogram incorporating the radiomics signature and important clinical predictors (CEA and CA19-9 for predicting GR; CEA, posttreatment length and posttreatment thickness for predicting pCR) achieved favorable prediction efficacy, with AUCs of 0.918 (95% confidence interval [CI]: 0.867-0.971, Sen = 0.972, Spe = 0.828) and 0.944 (95% CI: 0.891-0.997, Sen = 0.943, Spe = 0.828) in the training and validation cohort for predicting GR, respectively; with AUCs of 0.959 (95% CI: 0.927-0.991, Sen = 1.000, Spe = 0.833) and 0.912 (95% CI: 0.843-0.982, Sen = 1.000, Spe = 0.815) in the training and validation cohort for predicting pCR, respectively. Decision curve analysis confirmed potential clinical usefulness of our nomogram. CONCLUSIONS: This study demonstrated that the MRI-based radiomics nomogram is predictive of response to nCRT and can be considered as a promising tool for facilitating treatment decision-making for patients with LARC.
PURPOSE: To investigate the value of multiparametric MRI-based radiomics on predicting response to nCRT in patients with rectal cancer. METHODS: This study enrolled 193 patients with pathologically confirmed LARC who received nCRT treatment between Apr. 2014 and Jun. 2018. All patients underwent baseline T1-weighted (T1W), T2-weighted (T2W) and T2-weighted fat-suppression (T2FS) MRI scans before neoadjuvant chemoradiotherapy. Radiomics features were extracted and selected from the MRI data to establish the radiomics signature. Important clinical predictors were identified by Mann-Whitney U test and Chi-square test. The nomogram integrating the radiomics signature and important clinical predictors was constructed using multivariate logistic regression. Prediction capabilities of each model were assessed with receiver operating characteristic (ROC) curve analysis. Performance of the nomogram was evaluated by its calibration and potential clinical usefulness. RESULTS: For the prediction of good response (GR) and pathologic complete response (pCR), the developed radiomics signature comprising 10 and 7 features, respectively, were significantly associated with the therapeutic response to nCRT. The nomogram incorporating the radiomics signature and important clinical predictors (CEA and CA19-9 for predicting GR; CEA, posttreatment length and posttreatment thickness for predicting pCR) achieved favorable prediction efficacy, with AUCs of 0.918 (95% confidence interval [CI]: 0.867-0.971, Sen = 0.972, Spe = 0.828) and 0.944 (95% CI: 0.891-0.997, Sen = 0.943, Spe = 0.828) in the training and validation cohort for predicting GR, respectively; with AUCs of 0.959 (95% CI: 0.927-0.991, Sen = 1.000, Spe = 0.833) and 0.912 (95% CI: 0.843-0.982, Sen = 1.000, Spe = 0.815) in the training and validation cohort for predicting pCR, respectively. Decision curve analysis confirmed potential clinical usefulness of our nomogram. CONCLUSIONS: This study demonstrated that the MRI-based radiomics nomogram is predictive of response to nCRT and can be considered as a promising tool for facilitating treatment decision-making for patients with LARC.
Authors: Monique Maas; Regina G H Beets-Tan; Doenja M J Lambregts; Guido Lammering; Patty J Nelemans; Sanne M E Engelen; Ronald M van Dam; Rob L H Jansen; Meindert Sosef; Jeroen W A Leijtens; Karel W E Hulsewé; Jeroen Buijsen; Geerard L Beets Journal: J Clin Oncol Date: 2011-11-07 Impact factor: 44.544
Authors: Doenja M J Lambregts; Monique Maas; Thierry N Boellaard; Andrea Delli Pizzi; Marit E van der Sande; Britt J P Hupkens; Max J Lahaye; Frans C H Bakers; Geerard L Beets; Regina G H Beets-Tan Journal: Eur Radiol Date: 2019-08-19 Impact factor: 5.315
Authors: Philippe Lambin; Ralph T H Leijenaar; Timo M Deist; Jurgen Peerlings; Evelyn E C de Jong; Janita van Timmeren; Sebastian Sanduleanu; Ruben T H M Larue; Aniek J G Even; Arthur Jochems; Yvonka van Wijk; Henry Woodruff; Johan van Soest; Tim Lustberg; Erik Roelofs; Wouter van Elmpt; Andre Dekker; Felix M Mottaghy; Joachim E Wildberger; Sean Walsh Journal: Nat Rev Clin Oncol Date: 2017-10-04 Impact factor: 66.675
Authors: In Ja Park; Y Nancy You; Atin Agarwal; John M Skibber; Miguel A Rodriguez-Bigas; Cathy Eng; Barry W Feig; Prajnan Das; Sunil Krishnan; Christopher H Crane; Chung-Yuan Hu; George J Chang Journal: J Clin Oncol Date: 2012-04-09 Impact factor: 44.544
Authors: Monique Maas; Patty J Nelemans; Vincenzo Valentini; Prajnan Das; Claus Rödel; Li-Jen Kuo; Felipe A Calvo; Julio García-Aguilar; Rob Glynne-Jones; Karin Haustermans; Mohammed Mohiuddin; Salvatore Pucciarelli; William Small; Javier Suárez; George Theodoropoulos; Sebastiano Biondo; Regina G H Beets-Tan; Geerard L Beets Journal: Lancet Oncol Date: 2010-08-06 Impact factor: 41.316
Authors: Iram Shahzadi; Alex Zwanenburg; Annika Lattermann; Annett Linge; Christian Baldus; Jan C Peeken; Stephanie E Combs; Markus Diefenhardt; Claus Rödel; Simon Kirste; Anca-Ligia Grosu; Michael Baumann; Mechthild Krause; Esther G C Troost; Steffen Löck Journal: Sci Rep Date: 2022-06-17 Impact factor: 4.996